Actively Recruiting
Application Value of Novel PET Tracers Targeting CAF in ANCA-Associated Vasculitis
Led by Ruijin Hospital · Updated on 2025-11-17
30
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), a condition where lung and kidney involvement often leads to worse outcomes. This study aims to evaluate a new PET imaging tracer, 68Ga-Fibroblast Activation Protein Inhibitor (FAPI), which targets activated fibroblasts to detect disease activity and lesion distribution in AAV patients. Early and accurate diagnosis using this novel tracer could help personalize treatment and better assess disease severity and prognosis. The study will observe patients with AAV, including those with or without interstitial lung disease and renal dysfunction, using the 68Ga-FAPI PET/CT scan. This noninvasive imaging technique allows whole-body disease localization in a single exam. The study will compare disease severity and activity as measured by the PET/CT scan within four weeks after enrollment. No experimental treatments are administered since this is an observational study. Participants will undergo clinical evaluations and the PET/CT imaging to assess disease activity and severity. Researchers will collect clinical information and imaging data to provide insights on lesion distribution and organ involvement. The study requires informed consent and cooperation throughout the process. Total participation time varies, with the primary outcome measured within four weeks post-enrollment. Safety and compliance will be monitored during the study period, which runs until July 2028.
CONDITIONS
Brief Title
(68)Ga-FAPI PET/CT in Patients With ANCA-associated Vasculitis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age over 18 years
- Meet the 2022 ACR/EULAR classification criteria for ANCA-associated vasculitis
- Diagnosed with interstitial lung disease based on high-resolution CT images within one year prior to enrollment
- Have complete clinical information available
- Provide signed and dated informed consent
- Willing to comply with study procedures and cooperate throughout the study
You will not qualify if you...
- Have other rheumatic diseases
- Have other conditions causing interstitial lung disease or kidney impairment such as systemic lupus erythematosus, dermatomyositis, or rheumatoid arthritis
- History of or planned hematopoietic stem cell transplantation
- Severe comorbidities like severe cardiopulmonary insufficiency, bone marrow suppression, or liver/kidney failure
- Acute abdominal emergencies such as intestinal perforation or obstruction
- Pregnant, potentially pregnant, or breastfeeding women
- Poor treatment compliance
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Within 4 weeks after enrollment
Participants undergo 68Ga-FAPI PET/CT imaging to assess disease severity and activity in ANCA-associated vasculitis with interstitial lung disease and renal dysfunction.
1 visit (in-person)
Trial Site Locations
Total: 1 location
1
Ruiiin Hospital Shanghai JiaoTong University School of Medicine
Shanghai, China, 200025
Actively Recruiting
Research Team
H
Hong-Lei Liu
J
Jiajia Hu
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here